Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and
Chief Commercial Officer
MOUNTAIN VIEW, Calif., March 13, 2013
MOUNTAIN VIEW, Calif., March 13, 2013 /PRNewswire/ --Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) announced today that Peter W. Schineller has joined the
company as Senior Vice President and Chief Commercial Officer.
Mr. Schineller brings more than twenty years of industry experience directing
sales and marketing efforts at multinational pharmaceutical and specialty
pharmaceutical companies for numerous diagnostic and therapeutic products. In
this newly created role, Mr. Schineller will be responsible for overseeing
Alexza's global commercialization efforts and strategies for ADASUVE^®,
reporting to Thomas B. King, Alexza's President and Chief Executive Officer.
"With the recent approval of ADASUVE in the US and EU, this is an exciting
time to join the talented team at Alexza," said Mr. Schineller. "Alexza is
putting in place a number of important launch preparatory activities, and we
are focused on having the elements we believe will support a successful
commercial launch of ADASUVE in the U.S. and in Europe."
"We are very pleased to welcome Peter to Alexza as a member of our management
team. He brings a wealth of commercial experience in many settings and with
many products," said Thomas B. King, Alexza President and CEO. "The approvals
of ADASUVE in the U.S. and the EU now make ADASUVE a global brand. Peter will
lead our commercialization strategies for ADASUVE as we focus on product
launches later this year. Moreover, Peter's diverse experience in introducing
and promoting healthcare products is a great fit for contributing to Alexza
and shaping our product pipeline opportunities."
Mr. Schineller was most recently Senior Vice President and General Manager at
Ventana Medical Systems, a diagnostic company owned by Roche. From August
2011 to September 2012, Mr. Schineller was a Principal at the Fidelis
Consulting Group, providing commercial consulting expertise to the healthcare
industry. From July 2010 to July 2011, Mr. Schineller was Senior Vice
President Sales, Marketing and Commercial Operations at Genoptix Medical
Laboratories, a diagnostic company, which was acquired by Novartis. From July
2008 to July 2010, Mr. Schineller was with Cypress Bioscience, a
pharmaceutical company, serving as its Vice President Sales, Diagnostic
Marketing and Managed Healthcare from August 2008. From November 2002 to June
2008, Mr. Schineller was Co-Founder and Senior Vice President, Sales and
Marketing at Verus Pharmaceuticals, and he has also previously held positions
at Elan Biopharmaceuticals, Inc., Dura Pharmaceuticals, Inc. and Abbott
Laboratories, Inc. Prior to entering the healthcare industry, Mr. Schineller
served as a Commissioned Officer in the United States Marine Corps where he
attained the rank of Captain. Mr. Schineller holds a BA degree from the State
University of New York at Stony Brook.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions, including agitation, acute repetitive
seizures and insomnia. Alexza's products are based on the Staccato^® system,
a hand-held inhaler that is designed to deliver a drug aerosol to the deep
lung, providing rapid systemic delivery and therapeutic onset with ease and
convenience for patients.
ADASUVE^® (Staccato loxapine) is Alexza's first approved product, which was
approved by the U.S. Food and Drug Administration in December 2012 and by the
European Medicines Agency in February 2013. Grupo Ferrer Internacional, S.A.
is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia
and the Commonwealth of Independent States countries. The commercial launch
of ADASUVE is planned for the third quarter 2013 in the U.S. and Europe.
For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit www.alexza.com. For more
information about ADASUVE, please visit www.adasuve.com.
ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,
Safe Harbor Statement
This news release includes forward-looking statements that involve significant
risks and uncertainties. Any statement describing the Company's expectations
or beliefs is a forward-looking statement, as defined in the Private
Securities Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of developing and commercializing
drugs, including the ability for Alexza and Ferrer to effectively and
profitably commercialize ADASUVE, the adequacy of the Company's capital to
support the Company's operations, and the Company's ability to raise
additional funds and the potential terms of such potential financings. The
Company's forward-looking statements also involve assumptions that, if they
prove incorrect, would cause its results to differ materially from those
expressed or implied by such forward-looking statements. These and other risks
concerning Alexza's business are described in additional detail in the
Company's Annual Report on Form 10-K for the year ended December 31, 2011 and
the Company's other Periodic and Current Reports filed with the Securities and
Exchange Commission. Forward-looking statements contained in this announcement
are made as of this date, and the Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.
Contact: BCC Partners, Karen L. Bergman and Michelle Corral, +1-650-575-1509
or +1-415-794-8662, firstname.lastname@example.org or email@example.com
Press spacebar to pause and continue. Press esc to stop.